Adlai Nortye Ltd. American Depositary Shares

Healthcare US ANL

11.26USD
-0.32(2.76%)

Last update at 2026-06-03T20:00:00Z

Day Range

10.2111.79

LowHigh

52 Week Range

0.8817.25

LowHigh

Fundamentals

Previous Close 11.58
Market Cap881.08M
Volume229863
P/E Ratio-
Dividend Yield-%
EBITDA-34.93500M
Revenue TTM5.00M
Revenue Per Share TTM0.16
Gross Profit TTM 5.00M
Diluted EPS TTM-1.11

Overview
Financials
Peer Comparison
Reports
Stock Research & News
Profile

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Type	yearly	yearly	yearly	yearly	yearly
Date	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Income before tax	-35.62196M	-51.89502M	-104.13740M	-58.79000M	-56.67800M
Minority interest	-	-	-	-	-
Net income	-35.62196M	-51.89502M	-104.77984M	-58.79000M	-56.67800M
Selling general administrative	7.79M	9.44M	15.29M	13.04M	12.45M
Selling and marketing expenses	-	-	2.23M	-	-
Gross profit	5.00M	-1.87094M	2.78M	-2.03857M	45.73M
Reconciled depreciation	1.41M	1.87M	2.22M	2.04M	1.83M
Ebit	-36.18946M	-49.94604M	-68.38151M	-59.39100M	-56.17100M
Ebitda	-34.77272M	-48.07510M	-66.16144M	-57.35000M	-54.34300M
Depreciation and amortization	1.42M	1.87M	2.22M	2.04M	1.83M
Non operating income net other	-	-	-	-	-
Operating income	-35.69800M	-54.89552M	-68.38151M	-67.27000M	-8.64600M
Other operating expenses	41.20M	54.90M	73.38M	67.27M	54.37M
Interest expense	1.54M	1.94M	0.79M	0.43M	0.58M
Tax provision	0.00000M	0.00000M	0.64M	0.00000M	0.00000M
Interest income	-	-	0.06M	0.55M	0.03M
Net interest income	-1.53100M	-1.94400M	-0.72900M	-0.43300M	-1.33700M
Extraordinary items	-	-	-	-	-
Non recurring	-	-	-	-	-
Other items	-	-	-	-	-
Income tax expense	-	-	0.64M	8.31M	-46.18800M
Total revenue	5.01M	0.00000M	5.00M	0.00000M	45.73M
Total operating expenses	40.70M	53.02M	71.16M	67.27M	54.37M
Cost of revenue	-	1.87M	2.22M	2.04M	-
Total other income expense net	0.57M	3.00M	-35.75589M	8.91M	-46.69500M
Discontinued operations	-	-	-	-	-
Net income from continuing ops	-35.52800M	-51.86900M	-104.87100M	-58.79000M	-56.67800M
Net income applicable to common shares	-	-	-	-58.79000M	-58.79000M
Preferred stock and other adjustments	-	-	-	-	-

Breakdown	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Type	yearly	yearly	yearly	yearly	yearly
Date	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Total assets	34.43M	71.27M	130.19M	72.59M	131.69M
Intangible assets	0.02M	0.04M	0.06M	0.09M	0.10M
Earning assets	-	-	-	-	-
Other current assets	1.72M	1.98M	2.34M	-	-
Total liab	42.76M	45.78M	50.79M	313.89M	317.11M
Total stockholder equity	-8.32203M	25.48M	79.40M	-241.29300M	-185.42800M
Deferred long term liab	-	-	-	-	-
Other current liab	3.74M	3.34M	4.89M	294.25M	3.22M
Common stock	0.01M	0.01M	0.01M	0.00400M	0.00400M
Capital stock	0.01M	0.01M	0.01M	10.98M	10.98M
Retained earnings	-464.84798M	-429.31800M	-373.09207M	-268.22100M	-209.43100M
Other liab	-	-	-	-	-
Good will	-	-	-	-	-
Other assets	-	-	0.00000M	-	-
Cash	23.79M	60.90M	91.49M	42.76M	64.13M
Cash and equivalents	-	-	-	-	-
Total current liabilities	41.63M	45.36M	50.32M	312.65M	17.50M
Current deferred revenue	-	5.00M	0.00000M	3.88M	-
Net debt	2.59M	-33.67600M	-59.94401M	-36.21400M	-50.78600M
Short term debt	25.25M	26.80M	31.08M	5.31M	11.29M
Short long term debt	24.58M	26.33M	30.36M	4.31M	10.46M
Short long term debt total	26.38M	27.23M	31.55M	6.54M	13.35M
Other stockholder equity	439.27M	459.33M	438.71M	40.21M	28.04M
Property plant equipment	-	-	-	-	-
Total current assets	26.89M	64.06M	101.20M	66.30M	124.54M
Long term investments	4.25M	4.16M	24.85M	-	-
Net tangible assets	-	-	-	-252.36200M	-
Short term investments	0.00000M	0.00700M	7.01M	21.29M	53.81M
Net receivables	1.39M	1.17M	0.36M	0.35M	1.93M
Long term debt	-	-	-	-	-
Inventory	-	-	0.00000M	-	-
Accounts payable	12.64M	10.15M	14.35M	13.10M	2.98M
Total permanent equity	-	-	-	-	-
Noncontrolling interest in consolidated entity	-	-	-	-	-
Temporary equity redeemable noncontrolling interests	-	-	-	-	-
Accumulated other comprehensive income	17.25M	-4.53500M	13.78M	-4.15900M	-1.00200M
Additional paid in capital	-	-	-	-	-
Common stock total equity	-	-	-	-	-
Preferred stock total equity	-	-	-	-	-
Retained earnings total equity	-	-	-	-	-
Treasury stock	-	-	-	-	-
Accumulated amortization	-	-	-	-	-
Non currrent assets other	0.25M	0.30M	0.28M	0.33M	0.46M
Deferred long term asset charges	-	-	-	-	-
Non current assets total	7.54M	7.21M	28.99M	6.29M	7.14M
Capital lease obligations	1.79M	0.90M	1.19M	2.24M	2.89M
Long term debt total	-	-	-	-	-

Breakdown	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Type	yearly	yearly	yearly	yearly	yearly
Date	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Investments	-15.39300M	28.07M	-10.95400M	28.38M	-54.85700M
Change to liabilities	-	-	-	10.12M	0.00000M
Total cashflows from investing activities	-15.62120M	28.07M	-	-	-
Net borrowings	-2.64300M	-4.86000M	-	-6.48800M	-6.48800M
Total cash from financing activities	-3.82208M	-6.57900M	116.14M	-6.78000M	97.20M
Change to operating activities	-	-	-	-	-
Net income	-35.62196M	-51.86900M	-104.77984M	-58.79000M	-56.67800M
Change in cash	-37.11573M	-30.59000M	48.73M	-21.37300M	39.87M
Begin period cash flow	60.90M	91.49M	42.76M	64.13M	24.26M
End period cash flow	23.79M	60.90M	91.49M	42.76M	64.13M
Total cash from operating activities	-33.53947M	-51.81900M	-56.54081M	-43.22300M	-3.03400M
Issuance of capital stock	0.00000M	0.00000M	91.78M	0.00000M	-
Depreciation	1.42M	1.87M	2.22M	2.04M	1.83M
Other cashflows from investing activities	-	0.73M	-	-	-
Dividends paid	0.00000M	0.00000M	0.00000M	0.00000M	0.00000M
Change to inventory	-	-	-	-	-
Change to account receivables	-	-	-	-	-
Sale purchase of stock	-	-	-	-	-
Other cashflows from financing activities	-1.80677M	-1.87108M	117.34M	7.61M	108.60M
Change to netincome	-	-	-	-1.72100M	-1.72100M
Capital expenditures	0.19M	0.17M	0.20M	1.27M	1.12M
Change receivables	-	-	-	-	-
Cash flows other operating	-	-	-	-	-
Exchange rate changes	-	-	-	-	-
Cash and cash equivalents changes	-	-	-	-	-
Change in working capital	-2.29204M	-5.54000M	1.77M	15.25M	0.25M
Stock based compensation	1.53M	2.45M	4.33M	6.08M	3.39M
Other non cash items	2.96M	1.27M	47.44M	-6.76200M	48.25M
Free cash flow	-33.72696M	-51.98900M	-56.74063M	-44.49100M	-4.15400M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company	Change (USD)	Price (USD)	Trailing PE (x)	Forward PE (x)	Price Sales TTM (x)	Price to Book Value (x)	Enterprise Value to Revenue (x)
ANL Adlai Nortye Ltd. American Depositary Shares	-0.32 2.76%	11.26	-	-	176.22	82.76	173.51
NVO Novo Nordisk A/S	-0.92 2.14%	42.00	41.58	31.15	2.13	32.99	2.11	4.70
NONOF Novo Nordisk A/S	-0.75 1.73%	42.50	41.06	31.25	2.08	33.11	2.11	4.70
VRTX Vertex Pharmaceuticals Inc	3.25 0.76%	428.34	29.67	24.33	10.38	5.83	9.33	20.00
REGN Regeneron Pharmaceuticals Inc	16.03 2.66%	618.95	29.07	20.12	7.57	3.82	6.95	19.42

Reports Covered

View All

Profile

Adlai Nortye Ltd., a clinical-stage biotechnology company, engages in the research and develops pharmaceutical products in the United States and internationally. Its lead product is AN8025, a tri-functional fusion protein of aPD-L1 x CD86 variant x LAG3 variant, a T-cell and antigen-presenting cell modulator, which is in phase 1a clinical trials for the treatment of tumor. The company also developing AN9025, an oral small molecule pan-RAS(ON) inhibitor, which is in phase 1a clinical trials for the treatment of RAS-mutant cancers include pancreatic, lung, and colorectal adenocarcinomas; and AN4005, a first-in-class oral small-molecule PD-L1 inhibitor, which is in phase 1b treatment for tumor to activate cancer immunity. It is also developing AN0025, a small molecule EP4 antagonist, which is in phase 1b clinical trials for the treatment of locally advanced esophageal cancer (+chemoradiation therapy), and radiotherapy which is in phase 2 clinical trials for the treatment of rectal cancer (+chemoradiation therapy). Adlai Nortye Ltd. was founded in 2004 and is based in Grand Cayman, the Cayman Islands.

Adlai Nortye Ltd. American Depositary Shares

Ugland House, Grand Cayman, Cayman Islands, KY1-1104

848 230 7430
https://www.adlainortye.com
Employees : 109

Key Executives

Name	Title	Year Born
Mr. Yang Lu	CEO & Chairman	1981
Ms. Wei Zhang	Chief Financial Officer	1991
Dr. Kaiyang Tang	Senior VP & Global Head of Clinical Operations	1964
Dr. Victoria Elizabeth Demby Ph.D.	Senior VP & Global Head of Regulatory Affairs	1970
Dr. Ngai Chiu Tse M.D., Ph.D.	Head of Research & Development	1968
Mr. Yang Lu	Co- Founder, CEO & Chairman	1979
Dr. Ngai Chiu Tse M.D., Ph.D.	President & Head of Research & Development	1968
Dr. Xiaofeng Ye Ph.D.	Chief Financial Officer	1980
Dr. Zhiyong Yu Ph.D.	Vice President of Operations	NA
Mr. Chen Yang	Head of HR & Administration & Government Affairs	NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.